TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.
Status:
Recruiting
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
INFINITY is a Phase II, multicentre, single-arm, multi-cohort trial aimed at evaluating the
activity and safety of the combination of tremelimumab and durvalumab as neoadjuvant (Cohort
1) and definitive (Cohort 2) treatment for MSI-high gastric/gastroesophageal juction cancer
patients eligible for radical surgery.